

Company registration number: 762511

Banks Pharmacy Limited

Unaudited abridged financial statements

for the period from date of incorporation 22 April 2024 to 30 June 2025

Banks Pharmacy Limited

Contents

	Page
Directors responsibilities statement	1
Accountant's report	2
Balance sheet	3 - 4
Notes to the abridged financial statements	5 - 12

Banks Pharmacy Limited

Directors responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial period. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial period end date and of the profit or loss of the company for the financial period and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Banks Pharmacy Limited

**Accountants' Report to the board of directors
on the Unaudited abridged financial statements of Banks Pharmacy Limited**

In accordance with the engagement letter dated 15 July 2025, and in order to assist you to fulfil your duties under the Companies Act 2014, I have compiled the financial statements which comprise the , balance sheet and related notes from the accounting records and information and explanations you have given to me.

This report is made to the company's board of directors, as a body, in accordance with the terms of our engagement. My work has been undertaken so that I might compile the financial statements that I have been engaged to compile, report to the company's board of directors that I have done so, and state those matters that I have agreed to state to them in this report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the company and the company's board of directors for my work or for this report.

I have carried out this engagement in accordance with guidance issued by the Institute of Chartered Accountants in Ireland and have complied with the ethical guidance laid down by the Institute relating to members undertaking the compilation of financial statements.

You have acknowledged on the balance sheet for the financial period ended 30 June 2025 your duty under the Companies Act 2014 to ensure that the company has kept adequate accounting records and prepared financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial period and of its profit or loss for that financial period, and otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company. You consider that the company is exempt from the statutory requirement for an audit for the financial period.

I have not been instructed to carry out an audit of the financial statements. For this reason, I have not verified the accuracy or completeness of the accounting records or information and explanations you have given to me and I do not, therefore, express any opinion on the financial statements.

Haydon
Chartered Accountants

Quarterdeck Workspace
Ferry Terminal
Dun Laoghaire
Co Dublin

10 February 2026

Banks Pharmacy Limited

**Balance sheet
As at 30 June 2025**

	Note	30/06/25	
		€	€
Fixed assets			
Intangible assets	6	255,000	
Tangible assets	7	43,901	
		<u> </u>	298,901
 Current assets			
Stocks	8	61,720	
Debtors	9	84,366	
Cash at bank and in hand		142,752	
		<u> </u>	
		288,838	
 Creditors: amounts falling due within one year			
	10	(453,991)	
		<u> </u>	
Net current liabilities			(165,153)
Total assets less current liabilities			<u> </u>
			133,748
 Net assets			<u> </u>
			<u> </u>
 Capital and reserves			
Called up share capital presented as equity			100
Profit and loss account			133,648
			<u> </u>
Shareholders funds			<u> </u>
			<u> </u>

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 Financial Reporting Standard applicable in the UK and Republic of Ireland'.

The notes on pages 5 to 12 form part of these abridged financial statements.


Banks Pharmacy Limited

**Balance sheet (continued)
As at 30 June 2025**


We, as directors of Banks Pharmacy Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial period and of its profit or loss for such a financial period and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

These abridged financial statements were approved by the board of directors on 10 February 2026 and signed on behalf of the board by:



Richard Knightly
Director



Kevin Knightly
Director

The notes on pages 5 to 12 form part of these abridged financial statements.

Banks Pharmacy Limited

Notes to the abridged financial statements Financial period ended 30 June 2025

1. General information

The company is a private company limited by shares, registered in Ireland.(CRO number 762511) The address of the registered office is Quarterdeck Workspace, Ferry Terminal, Dun Laoghaire, Co Dublin.

2. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Going concern

The accounts are prepared on a going concern basis which assumes that the company will continue in existence for the foreseeable future with no intention to liquidate or significantly curtail its activities in the next 12 months. The directors are satisfied that it is appropriate for the financial statements to be prepared on a going concern basis.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Turnover is recognised to the extent that the company obtains the right to consideration in exchange for its performance. Turnover from sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer, usually at point of sale at the till, the amount of turnover can be measured reliably, it is probable that the economic benefits associated will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Taxation

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Goodwill

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business.

Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses.

Banks Pharmacy Limited

Notes to the abridged financial statements (continued)

Financial period ended 30 June 2025

Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

Goodwill - %

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

For impairment testing of goodwill, the goodwill acquired in a business combination is, from the acquisition date, allocated to each of the cash-generating units that are expected to benefit from the synergies of the combination, irrespective of whether other assets or liabilities of the company are assigned to those units.

Banks Pharmacy Limited

Notes to the abridged financial statements (continued) Financial period ended 30 June 2025

Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model and the performance model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Under the performance model, where the grant does not impose specified future performance-related conditions on the recipient, it is recognised in income when the grant proceeds are received or receivable. Where the grant does impose specified future performance-related conditions on the recipient, it is recognised in income only when the performance-related conditions have been met. Where grants received are prior to satisfying the revenue recognition criteria, they are recognised as a liability.

Banks Pharmacy Limited

Notes to the abridged financial statements (continued) Financial period ended 30 June 2025

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment.

Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets are either assessed individually or grouped on the basis of similar credit risk characteristics.

Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

Banks Pharmacy Limited

Notes to the abridged financial statements (continued) Financial period ended 30 June 2025

3. Staff costs

The average number of persons employed by the company during the financial period, including the directors was -.

	Period ended 30/06/25 2025 Number
Retail Assistants	5
Director	1
	<hr/> 6

The aggregate payroll costs incurred during the financial period were:

	Period ended 30/06/25 €
Wages and salaries	118,532
Social insurance costs	7,445
	<hr/> 125,977

4. Directors remuneration

The directors aggregate remuneration was as follows:

	Period ended 30/06/25 €
Emoluments in respect of qualifying services	44,820

5. Appropriations of profit and loss account

	30/06/25 €
At the start of the financial period	-
Profit for the financial period	133,648
At the end of the financial period	<hr/> 133,648

Banks Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial period ended 30 June 2025

6.	Intangible assets	Goodwill	Total
		€	€
	Cost		
	At 22 April 2024	-	-
	Additions	255,000	255,000
	At 30 June 2025	<u>255,000</u>	<u>255,000</u>
	Amortisation		
	At 22 April 2024 and 30 June 2025	-	-
	Carrying amount		
	At 30 June 2025	<u>255,000</u>	<u>255,000</u>
7.	Tangible assets	Fixtures, fittings and equipment	Computer equipment
		€	€
	Cost		Total
	At 22 April 2024	-	-
	Additions	46,713	4,657
	At 30 June 2025	<u>46,713</u>	<u>4,657</u>
	Depreciation		
	At 22 April 2024	-	-
	Charge for the financial period	5,839	1,630
	At 30 June 2025	<u>5,839</u>	<u>1,630</u>
	Carrying amount		
	At 30 June 2025	<u>40,874</u>	<u>3,027</u>
8.	Stocks		30/06/25
			€
	Finished goods and goods for resale		<u>61,720</u>

Banks Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial period ended 30 June 2025

9. Debtors

30/06/25

	€
Trade debtors	45,566
Other debtors	27,197
Prepayments	11,603
	<u>84,366</u>

10. Creditors: amounts falling due within one year

30/06/25

	€
Trade creditors	41,191
Other creditors including tax and social insurance	341,382
Accruals	71,418
	<u>453,991</u>

11. Directors transactions

During the financial period the company entered into the following arrangements relating to loans, quasi-loans and credit transactions:

Disclosure for each director or other person is as follows:

Richard Knightly

30/06/25

	€
At the start of the financial period	-
Advances made during the financial period	486
Amounts repaid during the financial period	(7,740)
	<u>(7,254)</u>

Kevin Knightly

30/06/25

	€
At the start of the financial period	-
Amounts repaid during the financial period	(309,000)
	<u>(309,000)</u>

Banks Pharmacy Limited

Notes to the abridged financial statements (continued)
Financial period ended 30 June 2025

12. Approval of financial statements

The board of directors approved these abridged financial statements for issue on 10 February 2026.